Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationPillar 3 · inherited risk, for you and your family
Heritage
Where Signature reads the tumour, Heritage reads you: the inherited changes that can raise cancer risk for you and your blood relatives.
Where Signature reads the tumour, Heritage reads you
Heritage looks at the inherited changes you were born with, the ones that can raise cancer risk for you and your blood relatives.
Is this part of a pattern the family should know about?
Why it matters
For you
An inherited change can shape treatment, because some cancers with germline changes respond to specific drugs. It also shapes future screening.
For your family
Finding a variant lets relatives choose testing, earlier screening and prevention. One test can protect a whole family.
For prevention
Knowing risk in advance turns cancer care from reactive to proactive.
The two tests
| Heritage Core | Heritage Adhoc | |
|---|---|---|
| What it is | A broad hereditary-cancer panel | A focused test for one known variant |
| Best when | You want a full inherited-risk assessment | A family variant is already known |
| Who it helps | You, and through you your family | Relatives of someone with a known variant |
| Scope | Broad inherited-risk assessment | One known family variant |
Counselling is included
No result without support.
Inherited risk is sensitive. It touches family, children and difficult feelings. Every Heritage test includes genetic counselling through KPCIRC, before and after: to help you decide what you want to know, to explain results plainly, and to plan next steps.
You are never handed a life-changing result and left alone with it.
Video to come
What a genetic counselling session is actually like
Ratio16/9Length3 minutes
Film briefWanted for launch
Three-minute film with a KPCIRC genetic counsellor, and if consent allows, a family who has been through it. Cover the questions people are afraid to ask: do I have to know, do I have to tell my children, what happens if it is positive. Calm and unhurried. Captioned and dubbed into regional languages.
Two-camera interview on location, natural light, lapel mics. Unhurried pacing with room for pauses.
Must be in frame
- A KPCIRC genetic counsellor, named
- The questions people are actually afraid to ask: do I have to know, do I have to tell my children, what happens if it is positive
- Captions, and dubbed tracks in at least four regional languages
Must not be
- Filming a family unless consent covers every platform and can be withdrawn
- Editing for drama, or cutting on an emotional reaction
- Any implication that testing is the obviously right choice for everyone
- Draft alt text
- A genetic counsellor explaining what a counselling session involves and what happens after a result.
- Consent and rights
- Written model release covering web, print and social, worldwide, in perpetuity. If a real patient is shown, a separate media consent naming every platform, and a right to withdraw that we will honour.
How Heritage is arranged
~50%of carriers can be missed by guideline-only criteria
1finding can protect an entire family
Research and evidence
The science behind this
Multi-gene germline panels repeatedly find inherited risk that would otherwise be missed.
Study 1
Inherited risk is common, and often unexpected
Among 10,975 cancer patients tested with a broad germline panel, 10.3% carried a pathogenic variant, and many would not have been predicted from personal or family history alone.
Landry KK, et al. JCO Precision Oncology, 2024.
Study 2
Panels find actionable variants across the board
In a large colorectal cohort, 14.2% carried a pathogenic germline variant, with actionable findings across every age, ancestry and panel size.
Multigene panel study, JCO Precision Oncology, 2022.
Study 3
Guideline criteria miss carriers
When testing is restricted to guideline criteria, roughly half of carriers can be missed, which argues for broader testing.
Beitsch PD, et al. Journal of Clinical Oncology, 2019.
These independent, peer-reviewed studies describe the class of technology we use. They are shared for education. They are not results for any individual and not a promise of benefit.
Being clear about our limits
What we do and do not do
What we DO
- Assess inherited cancer risk for you
- Enable cascade testing to protect blood relatives
- Include KPCIRC genetic counselling before and after
- Flag inherited changes that can shape treatment
What we DON’T do
- Diagnose cancer or read the tumour
- Predict with certainty that a cancer will occur
- Test relatives without their own consent and counselling
- Replace clinical screening or specialist follow-up
Plain-language glossary (6 terms)
| Term | What it means |
|---|---|
| Germline | An inherited change, present from birth and passable to children. |
| Somatic | A change that arises in the tumour during life. Not inherited. |
| Pathogenic variant | A change known to be disease-causing. Here, one that raises cancer risk. |
| VUS | Variant of uncertain significance, a change whose meaning is not yet clear. |
| Penetrance | How likely a carrier is to actually develop the cancer. |
| Cascade testing | Testing blood relatives for a known family variant. |
Important information and regulatory status
Heritage is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner holding NABL (ISO 15189), CAP and CLIA accreditation, following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal